Aqr Capital Management LLC Cel Sci Corp Transaction History

Aqr Capital Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$8.68 - $27.49 $89,525 - $283,531	-10,314 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$12.0 - $27.64 $119,076 - $274,271	-9,923 Reduced 49.03%	10,314 $157,000
Q2 2020 Aug 17, 2020	SELL	$9.75 - $17.6 $58,929 - $106,374	-6,044 Reduced 23.0%	20,237 $302,000
Q1 2020 May 15, 2020	SELL	$7.54 - $17.05 $94,679 - $214,096	-12,557 Reduced 32.33%	26,281 $303,000
Q4 2019 Feb 14, 2020	SELL	$6.71 - $9.55 $845 - $1,203	-126 Reduced 0.32%	38,838 $355,000
Q3 2019 Nov 14, 2019	BUY	$6.0 - $9.6 $233,784 - $374,054	38,964 New	38,964 $348,000

27.1K

150K

Ticker CVM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,367,500
Market Cap $26.9M
Description
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical ...

Get notified when there are updates to the investment portfolio of Aqr Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Aqr Capital Management LLC with notifications on news.